Adaptive Biotechnologies CORP Form 4 insider transactions

Susan Bobulsky, Chief Commercial Officer, MRD of Adaptive Biotechnologies Corp, sold 3,000 shares of common stock on August 10, 2026 for $25.00 per share.

Susan Bobulsky, Chief Commercial Officer, MRD of Adaptive Biotechnologies Corp, sold 1,299 shares of common stock on July 30, 2026 for $24.00 per share.

Harlan S Robins, Chief Scientific Officer of Adaptive Biotechnologies Corp, sold 492,400 shares of common stock on July 21, 2026.

Susan Bobulsky, Chief Commercial Officer, MRD of Adaptive Biotechnologies Corp, sold 5,000 shares of common stock on July 16, 2026 for $23.00 per share.

Francis Lo, Chief People Officer of Adaptive Biotechnologies Corp, sold 105,762 shares of common stock on July 15, 2026 for $22.59 per share.

Harlan S. Robins, Chief Scientific Officer at Adaptive Biotechnologies Corp, reported the sale of company stock totaling over 386,000 shares.

Adaptive Biotechnologies Corp. reports significant stock transactions by Chief People Officer Francis Lo, including acquisitions and dispositions under a Rule 10b5-1 trading plan.

Adaptive Biotechnologies Corp. reports a transaction by Chief Commercial Officer Susan Bobulsky involving common stock.

Sharon Benzeno, Chief Commercial Officer of Adaptive Biotechnologies Corp, reported a series of stock transactions on June 26-29, 2026, including acquisitions and dispositions of common stock and stock options.

Adaptive Biotechnologies Corp. reports a transaction by Chief Commercial Officer Susan Bobulsky involving the sale of common stock.

Michelle Renee Griffin, a Director at Adaptive Biotechnologies Corp, reported transactions involving the acquisition and disposition of common stock, executed under a Rule 10b5-1 trading plan.

Chief Scientific Officer Harlan S. Robins sold 106,160 shares of Adaptive Biotechnologies common stock via a 10b5-1 plan.

Chief Commercial Officer Susan Bobulsky sold 5,000 shares of Adaptive Biotechnologies common stock via a 10b5-1 plan.

Chief People Officer Francis Lo executed a series of stock option exercises and sales under a Rule 10b5-1 trading plan.

Chief Commercial Officer Susan Bobulsky sold 11,000 shares of Adaptive Biotechnologies common stock via a 10b5-1 plan.

CFO Kyle Piskel sold 3,115 shares of Adaptive Biotechnologies to satisfy tax obligations related to RSU vesting.

President and COO Julie Rubinstein exercised options and sold shares of Adaptive Biotechnologies under a 10b5-1 plan.

President and COO Julie Rubinstein exercised options and sold shares of Adaptive Biotechnologies under a Rule 10b5-1 plan.

President and COO Julie Rubinstein exercised stock options and sold shares under a pre-established Rule 10b5-1 trading plan.

President and COO Julie Rubinstein exercised options and sold shares under a pre-established Rule 10b5-1 trading plan.

Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp, reported a series of stock transactions involving both acquisitions and dispositions of common stock.

Adaptive Biotechnologies Corp. reports a Form 4 filing detailing stock transactions by Chief People Officer Francis Lo, executed under a pre-arranged trading plan.

Harlan S. Robins, Chief Scientific Officer at Adaptive Biotechnologies Corp, reported the sale of 10,000 shares of common stock for $148,500, executed under a pre-arranged trading plan.

Adaptive Biotechnologies Corp. CEO and Chairman Chad M. Robins has sold a significant number of company shares through a pre-arranged trading plan.

Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp, reports significant stock transactions under a Rule 10b5-1 trading plan.

Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp, reported transactions involving the purchase and sale of company common stock under a Rule 10b5-1 trading plan.

Adaptive Biotechnologies Corp's President and COO, Julie Rubinstein, executed planned sales of common stock following option exercises in late March 2026.

Adaptive Biotechnologies' President and COO, Julie Rubinstein, executed pre-planned option exercises and subsequent sales of company common stock over three days in March 2026.

Adaptive Biotechnologies' President and COO, Julie Rubinstein, executed pre-planned option exercises and subsequent stock sales totaling 57,180 shares.

Adaptive Biotechnologies' President and COO, Julie Rubinstein, executed a series of planned stock option exercises and subsequent sales of common stock in mid-March 2026.